KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2023)

Historic Return on Capital Employed for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2023 value amounting to 0.17%.

  • AbCellera Biologics' Return on Capital Employed fell 3200.0% to 0.17% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.17%, marking a year-over-year decrease of 3200.0%. This contributed to the annual value of 0.23% for FY2024, which is 600.0% down from last year.
  • As of Q4 2023, AbCellera Biologics' Return on Capital Employed stood at 0.17%, which was down 3200.0% from 0.15% recorded in Q3 2023.
  • AbCellera Biologics' Return on Capital Employed's 5-year high stood at 0.32% during Q1 2021, with a 5-year trough of 0.17% in Q4 2023.
  • Moreover, its 3-year median value for Return on Capital Employed was 0.19% (2021), whereas its average is 0.12%.
  • Per our database at Business Quant, AbCellera Biologics' Return on Capital Employed crashed by -300bps in 2022 and then tumbled by -3800bps in 2023.
  • Over the past 3 years, AbCellera Biologics' Return on Capital Employed (Quarter) stood at 0.18% in 2021, then decreased by -17bps to 0.15% in 2022, then plummeted by -213bps to 0.17% in 2023.
  • Its Return on Capital Employed stands at 0.17% for Q4 2023, versus 0.15% for Q3 2023 and 0.08% for Q2 2023.